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4 Changes in serotonin 2A (5-HT 2A ) receptor signaling have been implicated in psychiatric disorders such as depression, schizophrenia, and anxiety (Naughton et al., 2000; Roth, 1994) . 5-HT 2 receptors are the targets of some of the treatments for these disorders (Baxter et al., 1995) . 5-HT 2A receptors desensitize after chronic agonist stimulation (Roth et al., 1995; Smith et al., 1999; Anji et al., 2000) . 5-HT 2A receptors are coupled through G q/11 proteins to phospholipase C (PLC) (Hide et al.,1989; Roth et al., 1998) . Upon activation of PLC, hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) generates diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ) (Berridge, 1987) . G receptor signaling in the hypothalamic paraventricular nucleus was measured by agonistinduced increases in plasma adrenocorticotrophic hormone (ACTH), corticosterone, and oxytocin levels. Oxytocin and corticotropin releasing hormone (CRH) are expressed by neurons in the hypothalamic paraventricular nucleus (Swanson and Sawchenko, 1983) . (-)DOI (1 mg/kg, s.c.) on hormone secretion (Zhang et al., 2002) . Thus, plasma hormone levels are an index of the function of 5-HT 2A receptor signaling in the hypothalamic paraventricular nucleus. The dose of (-)DOI for the chronic and acute treatment was 1 mg/kg, i.p., a sub-maximal dose for ACTH, corticosterone, and oxytocin responses (unpublished data).
Previous studies investigating DOI-induced 5-HT 2A receptor desensitization in rats indicate that DOI treatment for 8 days produces a tolerance to the discriminative stimulus properties of DOI (Smith et al., 1999) . Autoradiographic analysis (Smith et al., 1999) and binding studies indicate that rat cortical 5-HT 2A receptors were down-regulated after 8 days of (±)DOI treatment without a change in their affinity (K d ) (McKenna et al., 1989; Valdez et al., 2002) . While agonist-induced desensitization of 5-HT 2A receptors has been documented, the mechanism and time course for induction of this desensitization have not been previously described. The present study used (-)DOI to determine the time course and the mechanism by which chronic agonist treatment produces 5-HT 2A receptor desensitization in vivo.
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Materials and Methods
Animals
Male Sprague-Dawley rats Harlan Laboratories, Indianapolis, IN) were housed two per cage in an environment controlled for temperature, humidity, and lighting (7 AM-7 PM). Food and water were provided ad libitum. Eight rats were used per experimental group. All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals as approved by the Loyola University Institutional Animal Care and Use Committee (IACUC). injected at a dose of 1 mg/kg, i.p., when used for chronic treatment and injected at a dose of 1 mg/kg, s.c., for the challenge injections.
Experimental Procedures
The rats were handled for at least 7 days prior to the challenge injection and acclimated to a quiet environment to minimize stress and prevent plasma hormones from exceeding basal levels. Rats were randomly assigned to the various experimental groups, cage mates being placed within the same experimental groups. The body weight of each rat was recorded every other day.
Rats were injected with (-)DOI (1 mg/kg, i.p.) for 1, 4, and 7 days or 0.9% saline (1 ml/kg, i.p.) for 7 days. Rats receiving (-)DOI injections for 1 and 4 days were given injections of 0.9% saline (1 ml/kg, i.p.) on the days prior to the commencement of (-)DOI treatment. Thus, every group received injections for a total of 7 days, which allowed us JPET #62067 to control for injection effects. Twenty-four hours after the last DOI treatment, a challenge injection of (-)DOI (1 mg/kg, s.c.) was administered 15 or 30 minutes prior to sacrifice. Control rats received a 0.9% saline (1 ml/kg, s.c.) challenge injection 15 minutes prior to sacrifice. The trunk blood was collected in centrifuge tubes containing 0.5 ml of a 0.3 M EDTA (pH 7.4) solution. The plasma samples for radioimmunoassays (RIAs) were stored at -80°C. Whole brains were removed, frozen on dry ice, and stored at -80°C for biochemical and molecular analyses.
PLC Activity
Tissue from the treatment groups that received the saline challenge was used for the measurement of PLC activity. PLC activity was measured by the amount of inositol 1,4,5 trisphosphate (IP 3 ) produced by PLC in the membrane fraction of the isolated tissue, as previously described (Wolf and Schutz, 1997) . Briefly, 30 µg of membrane protein from frontal cortex was diluted into 100 µl total volume with a buffer containing 25 mM Hepes-Tris, 3 mM EGTA, 10 mM LiCl, 12 mM MgCl 2 , 1.44 mM sodium deoxycholate with 1 µM GTPγS, 300 nM free Ca 2+ , 3 µM 5-HT, and 1 mM unlabelled phosphatidyl inositol. The reaction tubes were kept on ice until the incubation period (20 minutes at 37°C) was started with 100 µM 3 H-phosphatidyl inositol. The reaction was stopped by addition of 0.9 ml CHCl 2 :MeOH (1:2) and 0.3 ml chloroform. The tubes were shaken vigorously for 90 seconds and centrifuged at room temperature for 90 seconds at 21,238 x g. 0.3 ml of the upper aqueous phase was mixed with 6 ml of scintillation cocktail and counted by a scintillation counter for 5 minutes. Protein concentrations in these membrane preparations were measured using the BCA protein assay kit (Pierce, Rockford, IL).
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Tissue Preparation
Frontal cortex from the treatment groups that received the 1 mg/kg (-)DOI challenge was used for the measurement of G αq , G α11 , RGS4, and RGS7 proteins.
Punches of the hypothalamic paraventricular nucleus from the treatment groups that did not receive a challenge injection were used for the measurements of G αq , and G α11
protein.
The paraventricular nucleus was dissected from a 700 µm coronal section obtained using a cryostat (-10°C) as previously described (Serres et al., 2000) . Both tissues were homogenized in 10 mM Tris buffer containing 0.1 M NaCl, 0.1 M EDTA, and a protease inhibitor cocktail (1:1000) (Sigma Chemical Co., St. Louis, MO). Protein concentrations in these homogenates were measured as described above.
Quantification of Protein Levels
General Procedure:
Solubilized proteins were loaded in the following amounts for the frontal cortex:
10 µg/lane for G αq , G α11 , RGS7; 15 µg/lane for RGS4 proteins; for the paraventricular nucleus: 4 µg/lane for G αq , and G α11 proteins. These proteins were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis containing 0.1% SDS, 12.5% acrylamide/bisacrylamide (30:0.2), 4.6 M urea, and 375 mM Tris, pH 8.7 (Blank and Exton, 1994) . Gels were designed to contain 6 samples from the control group (saline treatment) and 6 samples from one of the (-)DOI treatment groups. The proteins were electrophoretically transferred for 2 hours to nitrocellulose membranes. Membranes were 
Specific Protein Antibodies:
The G αq protein (~42 kDa) was detected using a rabbit polyclonal G αq antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 1:1,000 dilution for frontal cortex; 1:500 dilution for paraventricular nucleus). The G α11 protein (~40 kDa) was detected using a rabbit polyclonal G α11 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 1:1,000 dilution for frontal cortex; 1:500 dilution for paraventricular nucleus). The antibodies for G αq and G α11 proteins recognized two bands, both of which were included in the quantitation of the protein levels. The specificity of these antibodies was verified with preabsorption studies (unpublished data). The RGS4 protein (~35 kDa) was detected using a goat polyclonal RGS4 antibody (N-16, Santa Cruz Biotechnology, Santa Cruz, CA, 1:2,000 dilution). The RGS7 protein (~56 kDa) was detected using a rabbit (G αq , G α11 , and RGS7 proteins) were followed by a goat anti-rabbit secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 1:10,000 dilution for frontal cortex;
1:20,000 dilution for paraventricular nucleus). All of these secondary antibodies were conjugated to horseradish peroxidase.
Western Blot Data Analysis
Films were analyzed densitometrically using the Scion Image program (Frederick, MD). Gray scale density readings were calibrated using a transmission step wedge standard. The integrated optical densities (IOD) of each band were calculated as the sum of the densities of all of the pixels within the area of the band outlined. An area adjacent to the band was used to calculate the background density of the band. The background IOD was subtracted from the IOD of each band. Each experimental sample was measured in triplicate. Due to lack of tissue, this was only measured in duplicate.
Radioimmunoassay of Hormones
Plasma ACTH, corticosterone, (Li et al., 1993) and oxytocin (Li et al., 1997) concentrations were determined by radioimmunoassays as previously described.
Statistical Analyses
All data are presented as group mean ± SEM. Body weight data were analyzed by a one-way analysis of variance (ANOVA) with repeated measures and hormone data (ACTH, corticosterone, and oxytocin) were analyzed by a two-way ANOVA; both were followed by a Newman-Keuls' multiple range test. PLC activity was analyzed using oneway ANOVA, followed by a Newman-Keuls' post hoc analysis. G α11 , G αq , RGS4, and RGS7 protein levels were analyzed using a Student t-test. GB-STAT software (Dynamic This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Body Weights Across Treatments
Figure 1 The body weight of the rats progressively increased across time during the experiment (Fig. 1) . Daily injections of (-)DOI for 1, 4, and 7 days inhibited the rate of weight gain when compared to the saline controls (F (15,345) = 26.30, p < 0.0001). Figure 2 Treatment with (-)DOI decreased 5-HT-stimulated PLC activity in the frontal cortex of rats (F (3,26) = 12.96, p < 0.0001). 5-HT-stimulated PLC activity decreased 24% after 4 days (p < 0.01) and 30% after 7 days (p < 0.01) of (-)DOI treatment ( Fig. 2A) . (-)DOI treatment did not affect GTPγS-stimulated PLC activity in the frontal cortex (F (3,30) = 1.3, p = 0.296) (Fig. 2B ). (-)DOI treatment decreased the ratio of 5-HT-to GTPγS-stimulated PLC activity (F (3,26) = 12.13) by 4% after 1 day (p > 0.05), 29% after 4 days (p < 0.01), and 34% after 7 days (p < 0.01) (Fig. 2C ).
Agonist-Induced Desensitization of 5-HT-stimulated PLC Activity in Frontal Cortex
Levels of 5-HT 2A Signaling Proteins in Frontal Cortex
Figure 3 Treatment with (-)DOI did not significantly reduce the levels of G αq proteins following 1 day (p = 0.91) and 4 days (p = 0.57) of (-)DOI treatment (Fig. 3) . Treatment with (-)DOI for 7 days resulted in decreased levels of G αq proteins by 47% in homogenates of the frontal cortex (p < 0.05; Fig. 3 ). Levels of G α11 protein in homogenates of the frontal cortex were not significantly altered after 4 days (p = 0.84) or 7 days (p = 0.68) of treatment with (-)DOI (Table 1) .
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Agonist-Induced Desensitization of (-)DOI-Mediated Hormone Secretion
Figure 4 Basal plasma ACTH, corticosterone, and oxytocin levels were not significantly altered after 1, 4, and 7 daily injections of (-)DOI. An acute dose (i.e., a challenge dose) of (-)DOI was administered 15 or 30 minutes prior to the measurement of plasma hormone levels. The (-)DOI challenge injection increased oxytocin levels above the levels of saline controls after 7 days of saline treatment and after 1 day of (-)DOI treatment, but not after 4 and 7 days of (-)DOI treatment (F (2,78) = 26.0, p < 0.0001). The (-)DOI challenge injection alone, without any (-)DOI pretreatment, increased plasma levels of oxytocin by 390% at 15 minutes and 414% at 30 minutes (p < 0.01) (Fig. 4A) .
The (-)DOI challenge injection increased ACTH levels above the levels of saline controls after 7 days of saline treatment and 1, 4 and 7 days of (-)DOI treatment (F (2,78) = 96.72, p < 0.0001). The (-)DOI challenge injection increased plasma levels of ACTH by 932% at 15 minutes and 1185% at 30 minutes (p < 0.01) (Fig. 4B) . The (-)DOI challenge injection increased corticosterone levels above the levels of saline controls after 7 days of saline treatment and 1, 4 and 7 days of (-)DOI treatment (F (2,78) = 78.81, p < 0.0001).
Plasma corticosterone levels were increased 255% at 15 minutes and 382% at 30 minutes (p < 0.01) (Fig. 4C ).
This article has not been copyedited and formatted. The final version may differ from this version. Treatment with (-)DOI did not alter basal hormone levels but it significantly reduced the oxytocin (F (3,78) = 11.1, p < 0.0001) and ACTH responses to a (-)DOI challenge (F (3,78) = 18.65, p < 0.0001) at both 15 and 30 minute post-injection (Fig. 4A,   B ). Treatment with (-)DOI did not alter the corticosterone response to the (-)DOI challenge injection at any time (F (3,78) = 6.15, p < 0.0008) (Fig. 4C) .
The ANOVA indicated that the interaction between the (-)DOI treatment and (- (Fig. 5A ). There were no significant differences between the 15 and 30 minute (-)DOI challenged groups.
(-)DOI treatment for 1 day significantly reduced the effect of (-)DOI on plasma ACTH levels by 25.1% (15 minutes post (-)DOI challenge injection; p < 0.05) and 50.6% (Fig. 4B ). There was no significant difference between the 15 and 30 minute (-)DOI challenged groups within the same treatment group. The (-)DOI-induced increase in plasma corticosterone levels was not affected by chronic (-)DOI treatment (F (6,89) = 1.60, p > 0.1) (Fig. 4C) .
Levels of 5-HT 2A Signaling Proteins in the Hypothalamic Paraventricular Nucleus
Treatment with (-)DOI did not produce a significant change in levels of G α11
proteins after 1 day (p = 0.77), 4 days (p = 0.21), or 7 days (p = 0.87) ( Table 2 ). Levels of G αq proteins in the hypothalamic paraventricular nucleus were not significantly altered after treatment with (-)DOI for 1 day (p = 0.9), 4 days (p = 0.95), or 7 days (p = 0.98) ( Table 2 ).
This article has not been copyedited and formatted. The final version may differ from this version. Treatment with (-)DOI does not produce a measurable change in (-)DOI-induced increase in plasma corticosterone levels, in concordance with previous studies (MazzolaPomietto et al., 1996) . ACTH stimulates corticosterone release from the adrenal cortex.
Previous studies have shown that plasma levels of ACTH exceeding 200-300 pg/ml produce a maximal increase in plasma corticosterone levels (Levy et al., 1992) . Thus, in the present experiment, although the ACTH response to a (-)DOI challenge injection was greatly reduced by pretreatment with (-)DOI, even these ACTH levels were elevated to such an extent that a maximal stimulation of the secretion of corticosterone was evident across the entire duration of the (-)DOI treatment. Hence, plasma corticosterone is the least sensitive peripheral marker of desensitized hypothalamic receptors. receptors in the frontal cortex desensitize after 7 days of (-)DOI treatment, but it is not likely involved in the desensitization of the 5-HT 2A receptors that occur after 4 days of (-)DOI treatment. In addition, even though there was a 47 % decrease in G α q protein levels after 7 days of (-)DOI treatment, there was no change in the GTPγS-stimulated PLC activity. While there is currently no definitive explanation for this phenomenon, it may be that G α 11 protein levels are sufficient to sustain GTPγS driven PLC activity as G α 11 protein levels were not reduced. Another explanation for this phenomenon is that there are two separate mechanisms of desensitization. One mechanism is activated within a few days of chronic treatment and is then succeeded by a decrease in G glioma cells is mediated by clathrin-mediated receptor internalization (Hanley and Hensler, 2002) . Other studies indicate that 5-HT 2A receptor internalization is cell type specific (Roth et al., 1995; Gray et al., 2001 (Roth et al., 1995) .
Since our present data suggest that DOI disrupts the receptor-to-G protein (Saltzman et al., 1991; Vouret-Craviari et al., 1995; Gray and Roth, 2001) . Recently, two phosphorylation sites on serine residues have been identified as critical for 5-HT 2A receptor desensitization in cell culture (Gray et al., 2003) . This article has not been copyedited and formatted. The final version may differ from this version. (1-way ANOVA and Newman-Keuls' post hoc). Table 1 Levels of G α11 , RGS4, and RGS7 proteins in the frontal cortex after (-)DOI treatment (1, 4, and 7 days). The data represent the mean IOD ± SEM as % of control (n = 6). G α11 , RGS4, and RGS7 protein levels did not change after (-)DOI treatment (Student t-test). NA = data not available due to insufficient amounts of tissue. Table 2 Levels of G α11 and G αq proteins in the paraventricular nucleus after (-)DOI treatment (1, 4, and 7 days). The data represent the mean IOD ± SEM as % of control (n = 6). G α11 and G αq protein levels did not change after (-)DOI treatment (Student ttest).
Treatment
Treatment Type G Chronic DOI Treatment (Days) 
